Scaling the immune incline in PDAC

Pancreatic ductal adenocarcinoma (PDAC) reflects the current challenge for immuno-oncology: to develop new drugs for cancers that are resistant to current immunotherapies. Here, we argue for a need to use patients to uncover new strategies that activate anti-tumour immunity.

Detalles Bibliográficos
Autores principales: Rojas, Luis A., Balachandran, Vinod P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173858/
https://www.ncbi.nlm.nih.gov/pubmed/34083798
http://dx.doi.org/10.1038/s41575-021-00475-9
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) reflects the current challenge for immuno-oncology: to develop new drugs for cancers that are resistant to current immunotherapies. Here, we argue for a need to use patients to uncover new strategies that activate anti-tumour immunity.

Ejemplares similares